Hans Adomat

Hans Adomat

Auto-generated profile, based on publicly available information

Hans Adomat

Vancouver Prostate Centre, Vancouver, British Columbia, Canada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
LRLouise Ramos
Louise Ramos
STSarah Truong
Sarah Truong
BZBeibei Zhai
Beibei Zhai
JJJay Joshi
Jay Joshi
FGFariba Ghaidi
Fariba Ghaidi
MDMads Daugaard
Mads Daugaard
Purpose: Histone deacetylase (HDAC) inhibition has been shown to induce pharmacologic “BRCAness” in cancer cells with proficient DNA repair activity. This provides a rationale for exploring combination treatments with HDAC and PARP inhibition in cancer types that are insensitive to single-agent PARP inhibitors (PARPi). Here, we report the concept and characterization of a novel bifunctional PARPi (kt-3283) with dual activity toward PARP1/2 and HDAC enzymes in Ewing sarcoma cells. Experimental Design: Inhibition of PARP1/2 and HDAC was measured using PARP1/2, HDAC activity, and PAR formation assays. Cytotoxicity was assessed by IncuCyte live cell imaging, CellTiter-Glo, and spheroid assays. Cell-cycle profiles were determined using propidium iodide staining and flow cytometry. DNA damage was examined by γH2AX expression and comet assay. Inhibition of metastatic potential by kt-3283 was evaluated via ex vivo pulmonary metastasis assay (PuMA). Results: Compared with FDA-approved PARP (olaparib) and HDAC (vorinostat) inhibitors, kt-3283 displayed enhanced cytotoxicity in Ewing sarcoma models. The kt-3283-induced cytotoxicity was associated with strong S and G2–M cell-cycle arrest in nanomolar concentration range and elevated DNA damage as assessed by γH2AX tracking and comet assays. In three-dimensional spheroid models of Ewing sarcoma, kt-3283 showed efficacy in lower concentrations than olaparib and vorinostat, and kt-3283 inhibited colonization of Ewing sarcoma cells in the ex vivo PuMA model. Conclusions: Our data demonstrate the preclinical justification for studying the benefit of dual PARP and HDAC inhibition in the treatment of Ewing sarcoma in a clinical trial and provides proof-of-concept for a bifunctional single-molecule therapeutic strategy.

4 December 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
BEBetul Ersoy-Fazlioglu
Betul Ersoy-Fazlioglu
SLShreyas Lingadahalli
Shreyas Lingadahalli
UAUmut Berkay Altintas
Umut Berkay Altintas
ACAhmet Cingoz
Ahmet Cingoz
ETEmirhan Tekoglu
Emirhan Tekoglu
NLNathan A. Lack
Nathan A. Lack
HOXB13 is a lineage-specific transcription factor that plays a critical role in initiation and progression of prostate cancer (PCa). While most research has focused on the role of HOXB13 on androgen receptor (AR) activity, here we demonstrate that HOXB13 is frequently expressed in AR-negative tumors and is essential for the proliferation of both AR-positive and -negative PCa models. Strikingly, HOXB13 is remarkably selective and has almost no effect on nonprostatic tissues. Despite this common essentiality in PCa, HOXB13 activity is markedly different in AR-negative stem cell–like tumors, where interactions with the AP-1 change the HOXB13 cistrome and interactome. Yet despite these distinct activities, HOXB13 activity is commonly mediated by SMARCD2, a member of the mSWI/SNF chromatin remodeling complex. The HOXB13/SMARCD2 interaction alters chromatin accessibility at HOXB13-binding sites, causing increased proliferation in AR-negative PCa. Overall, this work demonstrates a distinct mechanism of action for HOXB13 and highlights its critical role in AR-negative castration-resistant PCa.

27 January 2021 in The Prostate
Verified
Journal Article
Closed access
PDF file
PYParvin Yenki
Parvin Yenki
HAHans H. Adomat
Hans H. Adomat
COChristopher Ong
Christopher Ong

28 June 2023
Verified
Other
Open access
LRLouise Ramos
Louise Ramos
STSarah Truong
Sarah Truong
BZBeibei Zhai
Beibei Zhai
JJJay Joshi
Jay Joshi
FGFariba Ghaidi
Fariba Ghaidi
MDMads Daugaard
Mads Daugaard
Purpose:Histone deacetylase (HDAC) inhibition has been shown to induce pharmacologic “BRCAness” in cancer cells with proficient DNA repair activity. This provides a rationale for exploring combination treatments with HDAC and PARP inhibition in cancer types that are insensitive to single-agent PARP inhibitors (PARPi). Here, we report the concept and characterization of a novel bifunctional PARPi (kt-3283) with dual activity toward PARP1/2 and HDAC enzymes in Ewing sarcoma cells.Experimental Design:Inhibition of PARP1/2 and HDAC was measured using PARP1/2, HDAC activity, and PAR formation assays. Cytotoxicity was assessed by IncuCyte live cell imaging, CellTiter-Glo, and spheroid assays. Cell-cycle profiles were determined using propidium iodide staining and flow cytometry. DNA damage was examined by γH2AX expression and comet assay. Inhibition of metastatic potential by kt-3283 was evaluated via ex vivo pulmonary metastasis assay (PuMA).Results:Compared with FDA-approved PARP (olaparib) and HDAC (vorinostat) inhibitors, kt-3283 displayed enhanced cytotoxicity in Ewing sarcoma models. The kt-3283-induced cytotoxicity was associated with strong S and G2–M cell-cycle arrest in nanomolar concentration range and elevated DNA damage as assessed by γH2AX tracking and comet assays. In three-dimensional spheroid models of Ewing sarcoma, kt-3283 showed efficacy in lower concentrations than olaparib and vorinostat, and kt-3283 inhibited colonization of Ewing sarcoma cells in the ex vivo PuMA model.Conclusions:Our data demonstrate the preclinical justification for studying the benefit of dual PARP and HDAC inhibition in the treatment of Ewing sarcoma in a clinical trial and provides proof-of-concept for a bifunctional single-molecule therapeutic strategy.

25 November 2025
Verified
Other
Open access
LRLouise Ramos
Louise Ramos
STSarah Truong
Sarah Truong
BZBeibei Zhai
Beibei Zhai
JJJay Joshi
Jay Joshi
FGFariba Ghaidi
Fariba Ghaidi
MDMads Daugaard
Mads Daugaard
Replicate graphs of spheroid assays and cell fluorescence data

25 November 2025
Verified
Other
Open access
LRLouise Ramos
Louise Ramos
STSarah Truong
Sarah Truong
BZBeibei Zhai
Beibei Zhai
JJJay Joshi
Jay Joshi
FGFariba Ghaidi
Fariba Ghaidi
MDMads Daugaard
Mads Daugaard
Materials and methods for in vivo toxicity and cellular fluorescence assays